NASDAQ · KVUE
Consumer Defensive · Household & Personal Products
$18.98
Up+$0.23 (+1.19%)
Updated Aug 13, 2026, 7:46 PM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
KVUE closed at $18.98 after 21 trading sessions, up 1.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $18.69 | $19.06 | $18.65 | $18.98 | 11.03M |
| Aug 11, 2026 | $18.90 | $19.10 | $18.88 | $19.05 | 12.78M |
| Aug 10, 2026 | $19.03 | $19.16 | $18.89 | $19.03 | 25.55M |
| Aug 7, 2026 | $19.085 | $19.27 | $18.865 | $19.23 | 14.33M |
| Aug 6, 2026 | $19.54 | $19.70 | $19.01 | $19.18 | 25.33M |
| Aug 5, 2026 | $19.53 | $19.67 | $19.065 | $19.67 | 32.81M |
| Aug 4, 2026 | $19.00 | $19.61 | $18.685 | $19.55 | 23.6M |
| Aug 3, 2026 | $19.38 | $19.685 | $18.775 | $19.01 | 35.17M |
| Jul 31, 2026 | $19.19 | $19.34 | $18.95 | $19.24 | 22.74M |
| Jul 30, 2026 | $19.50 | $19.7737 | $19.095 | $19.31 | 16.3M |
| Jul 29, 2026 | $19.585 | $19.81 | $19.245 | $19.79 | 27.19M |
| Jul 28, 2026 | $19.72 | $20.046 | $19.69 | $19.75 | 19.63M |
| Jul 27, 2026 | $19.36 | $19.575 | $19.28 | $19.48 | 20.91M |
| Jul 24, 2026 | $18.88 | $19.28 | $18.83 | $19.28 | 21.43M |
| Jul 23, 2026 | $18.90 | $18.94 | $18.77 | $18.90 | 14.41M |
| Jul 22, 2026 | $19.21 | $19.235 | $19.045 | $19.13 | 9.9M |
| Jul 21, 2026 | $18.91 | $19.01 | $18.78 | $19.01 | 12.7M |
| Jul 20, 2026 | $18.93 | $19.08 | $18.895 | $19.02 | 12.22M |
| Jul 17, 2026 | $19.02 | $19.36 | $18.85 | $18.98 | 29.31M |
| Jul 16, 2026 | $18.85 | $19.10 | $18.775 | $19.02 | 15.95M |
| Jul 15, 2026 | $18.67 | $19.025 | $18.58 | $18.70 | 18.49M |
The latest Smart Investors Daily articles mentioning KVUE.
KVUE research
Company profile and research snapshot.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | UBS | Neutral | — |
| Jul 21, 2026 | Barclays | Equal-Weight | — |
| Jul 16, 2026 | UBS | Neutral | — |
| Apr 15, 2026 | Citigroup | Neutral | — |
| Apr 14, 2026 | Barclays | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
The Trump administration is reportedly considering an executive order on vaccines and autism as early as next week.
Yahoo · Aug 6, 2026
Sales and earnings increased across Kenvue's portfolio, but tariffs, inflation and currency costs reduced profitability.
Yahoo · Aug 6, 2026
Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.
Yahoo · Aug 6, 2026
Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KVUE.
